Suchergebnisse - "Agbarya, Abed"

PubPharm (55)

21

The Correlation between Proliferative Immunohistochemical Markers and Papillary Thyroid Carcinoma Aggressiveness

enthalten in: Medicina (Kaunas, Lithuania) | 2023

von Sheikh-Ahmad, M. | Shalata, Y. | Bejar, J. | +8

22

Impact of acupuncture and integrative therapies on chemotherapy-induced peripheral neuropathy : A multicentered, randomized controlled trial

enthalten in: Cancer | 2022

von Ben-Arye, E. | Hausner, D. | Samuels, N. | +8

23

FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)

enthalten in: Journal of clinical medicine | 2022

von Raphael, A. | Dudnik, E. | Hershkovitz, D. | +10

24

Real-World Journey of Unresectable Stage III NSCLC Patients : Current Dilemmas for Disease Staging and Treatment

enthalten in: Journal of clinical medicine | 2022

von Agbarya, A. | Shalata, W. | Addeo, A. | +9

25

Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer : A Retrospective, Single Institution Experience

enthalten in: Oncology | 2022

von Shalata, W. | Yakobson, A. | Weissmann, S. | +5

26

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs)

enthalten in: Frontiers in oncology | 2022

von Raphael, A. | Onn, A. | Holtzman, L. | +14

27

ONCOLOGY CARE CHALLENGES TREATING COVID-19 CONFIRMED CANCER PATIENTS : A REVIEW AND RECOMMENDATIONS

enthalten in: Harefuah | 2022

von Taha, T. | Agbarya, A.

28

Anti-androgen for myoepithelial tumor : a potent therapy yet a potential misleader

enthalten in: Anti-cancer drugs | 2022

von Hijab, A. | Taha, T. | Charas, T. | +3

29

Impact of acupuncture and integrative therapies on chemotherapy‐induced peripheral neuropathy : A multicentered, randomized controlled trial

enthalten in: Cancer | 2022

von Ben‐Arye, E. | Hausner, D. | Samuels, N. | +8

30

Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?

enthalten in: Current oncology (Toronto, Ont.) | 2021

von Shalata, W. | Yakobson, A. | Steckbeck, R. | +3